1429666-52-3

Upstream product

• 110744-85-9 4-chloromethyl-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]-decane 
• 1043894-61-6 (+)-pinanediol α-azidomethaneboronate 
• 172791-94-5 (3aS,4S,6S,7aR)-2-(bromomethyl)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole 
• 1425968-44-0 (+)-pinanediol (1R)-2-azido-1-[(2-thienylacetyl)amino]ethaneboronate 
• 536-74-3 phenylacetylene 
• 1425968-43-9 (+)-pinanediol (1R)-2-azido-1-[N,N-bis(trimethylsilyl)amino]ethaneboronate 
• 1043894-62-7 (+)-pinanediol (1S)-chloro-2-azidoethaneboronate 

Downstream Products

• 1429666-57-8 2-(4-phenyl-[1,2,3]triazol-1-yl)-1S-(2-thiophen-2-yl-acetylamino)ethaneboronic acid 

Relevant academic research and scientific papers

Click Chemistry in Lead Optimization of Boronic Acids as β-Lactamase Inhibitors

Boronic acid transition-state inhibitors (BATSIs) represent one of the most promising classes of β-lactamase inhibitors. Here we describe a new class of BATSIs, namely, 1-amido-2-triazolylethaneboronic acids, which were synthesized by combining the asymme

BORONIC ACID INHIBITORS OF BETA-LACTAMASES

The invention relates to novel boronic acid compounds, a method for the preparation of such compounds, intermediate compounds for the preparation of such compounds, intermediate compounds for the use in a method for preparation of such compounds, a pharmaceutical composition, the use of one or more compounds discussed above or of a pharmaceutical composition in the manufacture of a medicament for the treatment of a bacterial infection, and a screening method.